You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTravoprost
Accession NumberDB00287  (APRD01271)
TypeSmall Molecule
GroupsApproved
DescriptionTravoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin F2alpha analogue. [Wikipedia]
Structure
Thumb
Synonyms
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1e,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Travatan
Travatan Z
Travoprost
Travoprostum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IzbaEye drops, solution30 μg/mlOcular useAlcon Laboratories (Uk) Ltd2014-02-20Not applicableEu
IzbaEye drops, solution30 μg/mlOcular useAlcon Laboratories (Uk) Ltd2014-02-20Not applicableEu
Mylan-travoprost Zsolution0.004 %ophthalmicMylan Pharmaceuticals UlcNot applicableNot applicableCanada
PMS-travoprost Zsolution0.004 %ophthalmicPharmascience IncNot applicableNot applicableCanada
Sandoz Travoprostsolution0.004 %ophthalmicSandoz Canada Incorporated2014-08-15Not applicableCanada
Teva-travoprost Z Ophthalmic Solutionsolution0.004 %ophthalmicTeva Canada Limited2014-08-18Not applicableCanada
TravatanEye drops, solution40 μg /mlOcular useAlcon Laboratories (Uk) Ltd2001-11-27Not applicableEu
TravatanEye drops, solution40 μg /mlOcular useAlcon Laboratories (Uk) Ltd2001-11-27Not applicableEu
Travatansolution0.004 %ophthalmicAlcon Canada Inc2001-11-132010-11-16Canada
TravatanEye drops, solution40 μg /mlOcular useAlcon Laboratories (Uk) Ltd2001-11-27Not applicableEu
TravatanEye drops, solution40 μg /mlOcular useAlcon Laboratories (Uk) Ltd2001-11-27Not applicableEu
Travatan Zsolution/ drops.04 mg/mLophthalmicAlcon Laboratories, Inc2006-10-20Not applicableUs
Travatan Zsolution.04 mg/mLophthalmicPhysicians Total Care, Inc.2008-12-09Not applicableUs
Travatan Zsolution0.004 %ophthalmicAlcon Canada Inc2008-11-10Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-travoprost Zsolution0.004 %ophthalmicApotex Inc2014-08-14Not applicableCanada
Travoprost Ophthalmic Solution 0.004%solution.04 mg/mLophthalmicPar Pharmaceutical, Inc.2013-04-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Travo-ZNot Available
Brand mixtures
NameLabellerIngredients
Apo-travoprost-timopApotex Inc
Duotrav PqAlcon Canada Inc
Sandoz Travoprost / Timolol PqSandoz Canada Incorporated
SaltsNot Available
Categories
UNIIWJ68R08KX9
CAS number157283-68-6
WeightAverage: 500.5477
Monoisotopic: 500.238573467
Chemical FormulaC26H35F3O6
InChI KeyInChIKey=MKPLKVHSHYCHOC-AHTXBMBWSA-N
InChI
InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
IUPAC Name
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate
SMILES
CC(C)OC(=O)CCC\C=C/C[[email protected]]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentProstaglandins and related compounds
Alternative Parents
Substituents
  • Prostaglandin skeleton
  • Phenol ether
  • Fatty acid ester
  • Alkyl aryl ether
  • Benzenoid
  • Cyclopentanol
  • Monocyclic benzene moiety
  • Cyclic alcohol
  • Secondary alcohol
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationOphthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
PharmacodynamicsTravoprost, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analogue that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoporst free acid is potent and highly selective for the FP prostanoid receptor.
Mechanism of actionTravoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.
Related Articles
AbsorptionSystemically absorbed when administered to the eye.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the α(carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13,14 double bond.

Route of eliminationLess than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid.
Half lifeTerminal elimination half-life of travoprost free acid is 45 minutes.
ClearanceNot Available
ToxicitySymptoms of overexposure include irritation to the skin, eyes, nose, throat, and respiratory tract.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9857
Blood Brain Barrier+0.887
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.5907
P-glycoprotein inhibitor INon-inhibitor0.8237
P-glycoprotein inhibitor IINon-inhibitor0.6435
Renal organic cation transporterNon-inhibitor0.8856
CYP450 2C9 substrateNon-substrate0.8327
CYP450 2D6 substrateNon-substrate0.8383
CYP450 3A4 substrateSubstrate0.652
CYP450 1A2 substrateNon-inhibitor0.728
CYP450 2C9 inhibitorNon-inhibitor0.7607
CYP450 2D6 inhibitorNon-inhibitor0.9125
CYP450 2C19 inhibitorNon-inhibitor0.6844
CYP450 3A4 inhibitorNon-inhibitor0.8546
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7657
Ames testNon AMES toxic0.7427
CarcinogenicityNon-carcinogens0.9088
BiodegradationNot ready biodegradable0.9726
Rat acute toxicity3.5280 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9744
hERG inhibition (predictor II)Non-inhibitor0.6722
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon inc
Packagers
Dosage forms
FormRouteStrength
Solutionophthalmic
Eye drops, solutionOcular use30 μg/ml
Eye drops, solutionOcular use40 μg /ml
Solutionophthalmic0.004 %
Solution/ dropsophthalmic.04 mg/mL
Solutionophthalmic.04 mg/mL
Prices
Unit descriptionCostUnit
Travatan 0.004% Solution 5ml Bottle190.82USD bottle
Travatan Z 0.004% Solution 5ml Bottle190.82USD bottle
Travatan 0.004% Solution 2.5ml Bottle95.41USD bottle
Travatan Z 0.004% Solution 2.5ml Bottle95.41USD bottle
Travatan 0.004% eye drop45.87USD ml
Travatan z 0.004% eye drop36.7USD ml
Travatan 0.004 % Solution12.18USD ml
Travatan Z 0.004 % Solution12.18USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2129287 No2002-05-142014-08-02Canada
CA2181172 No2003-04-292015-12-19Canada
US5631287 No1994-12-222014-12-22Us
US6503497 No1995-05-062012-05-06Us
US8178582 No2009-10-102029-10-10Us
US8268299 No2009-10-132029-10-13Us
US8323630 No2007-09-202027-09-20Us
US8388941 No2007-09-202027-09-20Us
US8722735 No2009-10-102029-10-10Us
US8754123 No2009-05-192029-05-19Us
US9144561 No2009-03-132029-03-13Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
water solubility>16 mg/ml at 25.0°CNot Available
logP4.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00759 mg/mLALOGPS
logP4.02ALOGPS
logP3.84ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.95ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area96.22 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity127.86 m3·mol-1ChemAxon
Polarizability51.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. [PubMed:18452763 ]
  2. Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. doi: 10.1517/14656560903300129. [PubMed:19929706 ]
  3. Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9. [PubMed:9038626 ]
  4. Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20. doi: 10.1016/j.survophthal.2008.08.010. [PubMed:19038618 ]
  5. Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8. doi: 10.1517/14740330802465474 . [PubMed:18983226 ]
External Links
ATC CodesS01EE04
AHFS Codes
  • 52:92.00
PDB EntriesNot Available
FDA labelDownload (36.8 KB)
MSDSDownload (72.3 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Travoprost.
AcebutololTravoprost may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Aceclofenac.
Acetylsalicylic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Acetylsalicylic acid.
AdapaleneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Adapalene.
AlfuzosinAlfuzosin may increase the hypotensive activities of Travoprost.
AliskirenTravoprost may increase the hypotensive activities of Aliskiren.
AlprenololTravoprost may increase the hypotensive activities of Alprenolol.
AmbrisentanTravoprost may increase the hypotensive activities of Ambrisentan.
AmifostineTravoprost may increase the hypotensive activities of Amifostine.
AmlodipineTravoprost may increase the hypotensive activities of Amlodipine.
AntipyrineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Antipyrine.
ApremilastThe therapeutic efficacy of Travoprost can be decreased when used in combination with Apremilast.
AtenololTravoprost may increase the hypotensive activities of Atenolol.
AzapropazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Azapropazone.
AzelastineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Azelastine.
BalsalazideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Balsalazide.
BenazeprilTravoprost may increase the hypotensive activities of Benazepril.
BendroflumethiazideTravoprost may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Travoprost.
BenoxaprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Benoxaprofen.
BepridilTravoprost may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Travoprost.
BethanidineBethanidine may increase the hypotensive activities of Travoprost.
BimatoprostTravoprost may increase the hypotensive activities of Bimatoprost.
BisoprololTravoprost may increase the hypotensive activities of Bisoprolol.
BosentanTravoprost may increase the hypotensive activities of Bosentan.
BretyliumTravoprost may increase the hypotensive activities of Bretylium.
BrimonidineTravoprost may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Travoprost.
BromfenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bromfenac.
BupranololTravoprost may increase the hypotensive activities of Bupranolol.
CandesartanTravoprost may increase the hypotensive activities of Candesartan.
CandoxatrilTravoprost may increase the hypotensive activities of Candoxatril.
CaptoprilTravoprost may increase the hypotensive activities of Captopril.
CaroxazoneCaroxazone may increase the hypotensive activities of Travoprost.
CarprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Carprofen.
CarteololTravoprost may increase the hypotensive activities of Carteolol.
CarvedilolTravoprost may increase the hypotensive activities of Carvedilol.
CastanospermineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Castanospermine.
CelecoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Celecoxib.
CeliprololTravoprost may increase the hypotensive activities of Celiprolol.
ChloroquineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Chloroquine.
ChlorothiazideTravoprost may increase the hypotensive activities of Chlorothiazide.
ChlorthalidoneTravoprost may increase the hypotensive activities of Chlorthalidone.
CilazaprilTravoprost may increase the hypotensive activities of Cilazapril.
ClonidineTravoprost may increase the hypotensive activities of Clonidine.
ClonixinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Clonixin.
CryptenamineTravoprost may increase the hypotensive activities of Cryptenamine.
CyclothiazideTravoprost may increase the hypotensive activities of Cyclothiazide.
D-LimoneneThe therapeutic efficacy of Travoprost can be decreased when used in combination with D-Limonene.
DebrisoquinTravoprost may increase the hypotensive activities of Debrisoquin.
DeserpidineTravoprost may increase the hypotensive activities of Deserpidine.
DiazoxideDiazoxide may increase the hypotensive activities of Travoprost.
DiclofenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Diclofenac.
DiflunisalThe therapeutic efficacy of Travoprost can be decreased when used in combination with Diflunisal.
DiltiazemTravoprost may increase the hypotensive activities of Diltiazem.
DorzolamideTravoprost may increase the hypotensive activities of Dorzolamide.
DoxazosinTravoprost may increase the hypotensive activities of Doxazosin.
DroxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Droxicam.
EfonidipineTravoprost may increase the hypotensive activities of Efonidipine.
EnalaprilTravoprost may increase the hypotensive activities of Enalapril.
EnalaprilatTravoprost may increase the hypotensive activities of Enalaprilat.
EpirizoleThe therapeutic efficacy of Travoprost can be decreased when used in combination with Epirizole.
EpoprostenolTravoprost may increase the hypotensive activities of Epoprostenol.
EprosartanTravoprost may increase the hypotensive activities of Eprosartan.
EtanerceptThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etanercept.
EtodolacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etodolac.
EtofenamateThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etofenamate.
EtoricoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etoricoxib.
Evening primrose oilThe therapeutic efficacy of Travoprost can be decreased when used in combination with Evening primrose oil.
exisulindThe therapeutic efficacy of Travoprost can be decreased when used in combination with exisulind.
FelodipineTravoprost may increase the hypotensive activities of Felodipine.
FenbufenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Fenbufen.
FenoldopamTravoprost may increase the hypotensive activities of Fenoldopam.
FenoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Fenoprofen.
FloctafenineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Floctafenine.
FlunixinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Flunixin.
FlurbiprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Flurbiprofen.
FosinoprilTravoprost may increase the hypotensive activities of Fosinopril.
FurazolidoneFurazolidone may increase the hypotensive activities of Travoprost.
GuanabenzTravoprost may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Travoprost.
GuanethidineTravoprost may increase the hypotensive activities of Guanethidine.
GuanfacineTravoprost may increase the hypotensive activities of Guanfacine.
HexamethoniumTravoprost may increase the hypotensive activities of Hexamethonium.
HMPL-004The therapeutic efficacy of Travoprost can be decreased when used in combination with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Travoprost.
HydralazineTravoprost may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideTravoprost may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideTravoprost may increase the hypotensive activities of Hydroflumethiazide.
IbuprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ibuprofen.
IbuproxamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ibuproxam.
IcatibantThe therapeutic efficacy of Travoprost can be decreased when used in combination with Icatibant.
IloprostIloprost may increase the hypotensive activities of Travoprost.
IndapamideTravoprost may increase the hypotensive activities of Indapamide.
IndenololTravoprost may increase the hypotensive activities of Indenolol.
IndomethacinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Indomethacin.
IndoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Indoprofen.
IndoraminTravoprost may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Travoprost.
IproniazidIproniazid may increase the hypotensive activities of Travoprost.
IrbesartanTravoprost may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Travoprost.
IsoxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Isoxicam.
IsradipineIsradipine may increase the hypotensive activities of Travoprost.
KebuzoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Kebuzone.
KetoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ketorolac.
LabetalolTravoprost may increase the hypotensive activities of Labetalol.
LacidipineTravoprost may increase the hypotensive activities of Lacidipine.
LatanoprostTravoprost may increase the hypotensive activities of Latanoprost.
LeflunomideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Leflunomide.
LercanidipineTravoprost may increase the hypotensive activities of Lercanidipine.
LisinoprilTravoprost may increase the hypotensive activities of Lisinopril.
LofexidineTravoprost may increase the hypotensive activities of Lofexidine.
LornoxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lornoxicam.
LosartanTravoprost may increase the hypotensive activities of Losartan.
LoxoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Loxoprofen.
LumiracoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lumiracoxib.
MacitentanTravoprost may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe therapeutic efficacy of Travoprost can be decreased when used in combination with Magnesium salicylate.
ManidipineTravoprost may increase the hypotensive activities of Manidipine.
MasoprocolThe therapeutic efficacy of Travoprost can be decreased when used in combination with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Travoprost.
MecamylamineTravoprost may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Meclofenamic acid.
Mefenamic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mefenamic acid.
MeloxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Meloxicam.
MesalazineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mesalazine.
MetamizoleThe therapeutic efficacy of Travoprost can be decreased when used in combination with Metamizole.
MethyldopaTravoprost may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Travoprost.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Travoprost.
MetipranololTravoprost may increase the hypotensive activities of Metipranolol.
MetolazoneTravoprost may increase the hypotensive activities of Metolazone.
MetoprololMetoprolol may increase the hypotensive activities of Travoprost.
MibefradilTravoprost may increase the hypotensive activities of Mibefradil.
MinaprineMinaprine may increase the hypotensive activities of Travoprost.
MinoxidilTravoprost may increase the hypotensive activities of Minoxidil.
MoclobemideMoclobemide may increase the hypotensive activities of Travoprost.
MoexiprilTravoprost may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Travoprost.
MoxonidineTravoprost may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolic acid.
NabumetoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nabumetone.
NadololTravoprost may increase the hypotensive activities of Nadolol.
NaftifineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Naftifine.
NaproxenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Naproxen.
NCX 4016The therapeutic efficacy of Travoprost can be decreased when used in combination with NCX 4016.
NebivololTravoprost may increase the hypotensive activities of Nebivolol.
NepafenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nepafenac.
NialamideNialamide may increase the hypotensive activities of Travoprost.
NicardipineTravoprost may increase the hypotensive activities of Nicardipine.
NicorandilTravoprost may increase the hypotensive activities of Nicorandil.
Niflumic AcidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Niflumic Acid.
NiguldipineTravoprost may increase the hypotensive activities of Niguldipine.
NilvadipineTravoprost may increase the hypotensive activities of Nilvadipine.
NimesulideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nimesulide.
NimodipineTravoprost may increase the hypotensive activities of Nimodipine.
NisoldipineTravoprost may increase the hypotensive activities of Nisoldipine.
NitrendipineTravoprost may increase the hypotensive activities of Nitrendipine.
NitroprussideTravoprost may increase the hypotensive activities of Nitroprusside.
ObinutuzumabTravoprost may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Travoprost.
OlmesartanOlmesartan may increase the hypotensive activities of Travoprost.
OlopatadineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olopatadine.
OlsalazineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olsalazine.
OmapatrilatTravoprost may increase the hypotensive activities of Omapatrilat.
OrgoteinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Orgotein.
OxaprozinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Oxaprozin.
OxprenololTravoprost may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Oxyphenbutazone.
ParecoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Parecoxib.
PargylineTravoprost may increase the hypotensive activities of Pargyline.
PenbutololTravoprost may increase the hypotensive activities of Penbutolol.
PentoliniumTravoprost may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Travoprost.
PerindoprilTravoprost may increase the hypotensive activities of Perindopril.
PhenelzinePhenelzine may increase the hypotensive activities of Travoprost.
PheniprazinePheniprazine may increase the hypotensive activities of Travoprost.
PhenoxybenzamineTravoprost may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Travoprost.
PhentolamineTravoprost may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Phenylbutazone.
PimecrolimusThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pimecrolimus.
PinacidilTravoprost may increase the hypotensive activities of Pinacidil.
PindololTravoprost may increase the hypotensive activities of Pindolol.
PirfenidoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Travoprost.
PiroxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Travoprost.
PolythiazideTravoprost may increase the hypotensive activities of Polythiazide.
PrazosinTravoprost may increase the hypotensive activities of Prazosin.
PropacetamolThe therapeutic efficacy of Travoprost can be decreased when used in combination with Propacetamol.
PropranololTravoprost may increase the hypotensive activities of Propranolol.
PTC299The therapeutic efficacy of Travoprost can be decreased when used in combination with PTC299.
QuinaprilTravoprost may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Travoprost.
RamiprilRamipril may increase the hypotensive activities of Travoprost.
RasagilineRasagiline may increase the hypotensive activities of Travoprost.
RemikirenRemikiren may increase the hypotensive activities of Travoprost.
RescinnamineTravoprost may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Travoprost.
ResveratrolThe therapeutic efficacy of Travoprost can be decreased when used in combination with Resveratrol.
RiociguatTravoprost may increase the hypotensive activities of Riociguat.
RituximabTravoprost may increase the hypotensive activities of Rituximab.
RofecoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Rofecoxib.
SafrazineSafrazine may increase the hypotensive activities of Travoprost.
SalicylamideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salicylic acid.
SalsalateThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salsalate.
SaprisartanTravoprost may increase the hypotensive activities of Saprisartan.
SelegilineSelegiline may increase the hypotensive activities of Travoprost.
SelexipagTravoprost may increase the hypotensive activities of Selexipag.
SeratrodastThe therapeutic efficacy of Travoprost can be decreased when used in combination with Seratrodast.
SildenafilSildenafil may increase the antihypertensive activities of Travoprost.
SitaxentanTravoprost may increase the hypotensive activities of Sitaxentan.
SpiraprilTravoprost may increase the hypotensive activities of Spirapril.
SRT501The therapeutic efficacy of Travoprost can be decreased when used in combination with SRT501.
SulfasalazineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Sulfasalazine.
SulindacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Sulindac.
SuprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Travoprost.
TelmisartanTravoprost may increase the hypotensive activities of Telmisartan.
TemocaprilTravoprost may increase the hypotensive activities of Temocapril.
TenoxicamThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tenoxicam.
TepoxalinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tepoxalin.
TeriflunomideThe therapeutic efficacy of Travoprost can be decreased when used in combination with Teriflunomide.
TerlipressinTravoprost may increase the hypotensive activities of Terlipressin.
Tiaprofenic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid.
TiboloneTravoprost may increase the hypotensive activities of Tibolone.
TicrynafenTravoprost may increase the hypotensive activities of Ticrynafen.
TimololTravoprost may increase the hypotensive activities of Timolol.
TolazolineTravoprost may increase the hypotensive activities of Tolazoline.
Tolfenamic AcidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tolfenamic Acid.
TolmetinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Travoprost.
TorasemideTorasemide may increase the hypotensive activities of Travoprost.
TrandolaprilTravoprost may increase the hypotensive activities of Trandolapril.
TranilastThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Travoprost.
TranylcypromineTranylcypromine may increase the hypotensive activities of Travoprost.
TreprostinilTravoprost may increase the hypotensive activities of Treprostinil.
TrichlormethiazideTravoprost may increase the hypotensive activities of Trichlormethiazide.
TrimazosinTravoprost may increase the hypotensive activities of Trimazosin.
TrimethaphanTravoprost may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Travoprost.
UnoprostoneTravoprost may increase the hypotensive activities of Unoprostone.
ValdecoxibThe therapeutic efficacy of Travoprost can be decreased when used in combination with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Travoprost.
VardenafilVardenafil may increase the antihypertensive activities of Travoprost.
XylometazolineTravoprost may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Travoprost.
ZaltoprofenThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zaltoprofen.
ZileutonThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zileuton.
ZomepiracThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Prostaglandin f receptor activity
Specific Function:
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum (By similarity). Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and ...
Gene Name:
PTGFR
Uniprot ID:
P43088
Molecular Weight:
40054.1 Da
References
  1. Ota T, Aihara M, Narumiya S, Araie M: The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63. [PubMed:16249494 ]
  2. Thieme H, Schimmat C, Munzer G, Boxberger M, Fromm M, Pfeiffer N, Rosenthal R: Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):938-45. [PubMed:16505027 ]
  3. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. [PubMed:18452763 ]
  4. Neacsu AM: [Receptors involved in the mechanism of action of topical prostaglandines]. Oftalmologia. 2009;53(2):3-7. [PubMed:19697832 ]
  5. Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. doi: 10.1517/14656560903300129. [PubMed:19929706 ]
  6. Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9. [PubMed:9038626 ]
  7. Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20. doi: 10.1016/j.survophthal.2008.08.010. [PubMed:19038618 ]
  8. Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8. doi: 10.1517/14740330802465474 . [PubMed:18983226 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 02:14